Pacific Edge Limited
Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic produc… Read more
Pacific Edge Limited (PFGTF) - Net Assets
Latest net assets as of September 2025: $26.70 Million USD
Based on the latest financial reports, Pacific Edge Limited (PFGTF) has net assets worth $26.70 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($34.41 Million) and total liabilities ($7.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $26.70 Million |
| % of Total Assets | 77.59% |
| Annual Growth Rate | 17.06% |
| 5-Year Change | 3.89% |
| 10-Year Change | -12.49% |
| Growth Volatility | 205.42 |
Pacific Edge Limited - Net Assets Trend (2005–2025)
This chart illustrates how Pacific Edge Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pacific Edge Limited (2005–2025)
The table below shows the annual net assets of Pacific Edge Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $26.09 Million | -52.24% |
| 2024-03-31 | $54.62 Million | -38.22% |
| 2023-03-31 | $88.41 Million | -24.17% |
| 2022-03-31 | $116.60 Million | +364.36% |
| 2021-03-31 | $25.11 Million | +73.12% |
| 2020-03-31 | $14.50 Million | +4.27% |
| 2019-03-31 | $13.91 Million | -16.41% |
| 2018-03-31 | $16.64 Million | -20.11% |
| 2017-03-31 | $20.83 Million | -30.12% |
| 2016-03-31 | $29.81 Million | +178.51% |
| 2015-03-31 | $10.70 Million | -50.86% |
| 2014-03-31 | $21.78 Million | +95.40% |
| 2013-03-31 | $11.15 Million | -36.95% |
| 2012-03-31 | $17.68 Million | +557.01% |
| 2011-03-31 | $2.69 Million | +138.34% |
| 2010-03-31 | $1.13 Million | +338.97% |
| 2009-03-31 | $257.17K | -89.40% |
| 2008-03-31 | $2.43 Million | +620.26% |
| 2007-03-31 | $336.81K | -65.43% |
| 2006-03-31 | $974.17K | -12.82% |
| 2005-03-31 | $1.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pacific Edge Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 26627998000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $294.46 Million | 1128.84% |
| Other Comprehensive Income | $7.85 Million | 30.09% |
| Total Equity | $26.09 Million | 100.00% |
Pacific Edge Limited Competitors by Market Cap
The table below lists competitors of Pacific Edge Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Action Electronics Co Ltd
TW:3024
|
$69.35 Million |
|
SA Catana Group
PA:CATG
|
$69.35 Million |
|
P/F BankNordik
CO:BNORDIK-CSE
|
$69.40 Million |
|
SEPC Limited
NSE:SEPC
|
$69.44 Million |
|
BusinessOn Communication Co. Ltd
KQ:138580
|
$69.33 Million |
|
East Tender Opto
TWO:6588
|
$69.33 Million |
|
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
IS:GENIL
|
$69.33 Million |
|
Socovesa
SN:SOCOVESA
|
$69.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pacific Edge Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 54,622,000 to 26,085,000, a change of -28,537,000 (-52.2%).
- Net loss of 29,936,000 reduced equity.
- Other comprehensive income increased equity by 685,586.
- Other factors increased equity by 713,414.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-29.94 Million | -114.76% |
| Other Comprehensive Income | $685.59K | +2.63% |
| Other Changes | $713.41K | +2.73% |
| Total Change | $- | -52.24% |
Book Value vs Market Value Analysis
This analysis compares Pacific Edge Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.46x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.71x to 2.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | $0.03 | $0.08 | x |
| 2006-03-31 | $0.02 | $0.08 | x |
| 2007-03-31 | $0.00 | $0.08 | x |
| 2008-03-31 | $0.02 | $0.08 | x |
| 2009-03-31 | $0.00 | $0.08 | x |
| 2010-03-31 | $0.01 | $0.08 | x |
| 2011-03-31 | $0.01 | $0.08 | x |
| 2012-03-31 | $0.07 | $0.08 | x |
| 2013-03-31 | $0.03 | $0.08 | x |
| 2014-03-31 | $0.06 | $0.08 | x |
| 2016-03-31 | $0.08 | $0.08 | x |
| 2017-03-31 | $0.05 | $0.08 | x |
| 2018-03-31 | $0.04 | $0.08 | x |
| 2019-03-31 | $0.03 | $0.08 | x |
| 2020-03-31 | $0.02 | $0.08 | x |
| 2021-03-31 | $0.04 | $0.08 | x |
| 2022-03-31 | $0.15 | $0.08 | x |
| 2023-03-31 | $0.11 | $0.08 | x |
| 2024-03-31 | $0.07 | $0.08 | x |
| 2025-03-31 | $0.03 | $0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pacific Edge Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -114.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -137.03%
- • Asset Turnover: 0.59x
- • Equity Multiplier: 1.42x
- Recent ROE (-114.76%) is above the historical average (-165.09%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -254.88% | -5696.00% | 0.04x | 1.24x | $-2.96 Million |
| 2006 | -258.36% | 0.00% | 0.00x | 1.33x | $-2.61 Million |
| 2007 | -558.43% | 0.00% | 0.00x | 1.67x | $-1.91 Million |
| 2008 | -79.06% | -2339.02% | 0.03x | 1.31x | $-2.16 Million |
| 2009 | -962.01% | -1124.55% | 0.25x | 3.49x | $-2.50 Million |
| 2010 | -223.93% | 0.00% | 0.00x | 1.60x | $-2.64 Million |
| 2011 | -116.07% | -624600.00% | 0.00x | 1.22x | $-3.39 Million |
| 2012 | -23.07% | -2059.60% | 0.01x | 1.05x | $-5.85 Million |
| 2013 | -62.06% | -3800.55% | 0.01x | 1.10x | $-8.03 Million |
| 2014 | -45.69% | -1902.68% | 0.02x | 1.04x | $-12.13 Million |
| 2015 | -104.92% | -591.10% | 0.15x | 1.18x | $-12.30 Million |
| 2016 | -52.59% | -315.07% | 0.15x | 1.08x | $-18.66 Million |
| 2017 | -75.80% | -704.05% | 0.10x | 1.13x | $-17.87 Million |
| 2018 | -118.05% | -577.76% | 0.17x | 1.18x | $-21.31 Million |
| 2019 | -128.81% | -469.43% | 0.23x | 1.19x | $-19.31 Million |
| 2020 | -130.21% | -432.17% | 0.23x | 1.33x | $-20.34 Million |
| 2021 | -56.65% | -660.92% | 0.07x | 1.24x | $-16.73 Million |
| 2022 | -16.97% | -172.90% | 0.09x | 1.06x | $-31.45 Million |
| 2023 | -30.50% | -137.46% | 0.20x | 1.10x | $-35.81 Million |
| 2024 | -54.07% | -113.32% | 0.40x | 1.20x | $-35.00 Million |
| 2025 | -114.76% | -137.03% | 0.59x | 1.42x | $-32.54 Million |
Industry Comparison
This section compares Pacific Edge Limited's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pacific Edge Limited (PFGTF) | $26.70 Million | -254.88% | 0.29x | $69.34 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |